LEXINGTON, MA, TRIANA Biomedicines, a biopharmaceutical company, announced the successful closing of its oversubscribed $120 million Series B financing round.
TRIANA Biomedicines, a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, announced the successful closing of its oversubscribed $120 million Series B financing round.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
